Results 161 to 170 of about 214,341 (267)

Delafloxacin suppresses DEPDC1 expression and induces G2/M arrest in non‐small cell lung cancer cells: A drug repurposing study

Smart Molecules, EarlyView.
This study presents Delafloxacin repurposed as a DEPDC1‐targeting therapeutic aiming to suppress lung cancer progression. It highlights a novel strategy for lung cancer treatment with potential clinical applications. Abstract Emerging evidence highlights the oncogenic role of the Dishevelled, Egl‐10, and Pleckstrin domains containing 1 (DEPDC1) gene in
Noman Ali, Farishta Shafiq, Mishal Iftikhar, Muhammad Shahzad Zafar, Muhammad Shoaib   +4 more
wiley   +1 more source

Cost-effectiveness of neoadjuvant and adjuvant novel cancer therapies in stage II-III non-small cell lung cancer in Sri Lanka. [PDF]

BMJ Oncol
Joseph N, Kularatna S, Senanayake S.
europepmc   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Harnessing Gut Microbiota to Enhance Immunotherapy in NSCLC: From Mechanisms to Translational Applications. [PDF]

Cancer Med
Zhu L, Xu J, Niu D, Zhang X, Jin C.
europepmc   +1 more source

Integrative Bioinformatics, Experimental Validation, and Interpretable Machine Learning Reveal Oxyresveratrol‐Mediated Protection Against Cadmium‐Induced Lung Adenocarcinoma‐Related Transcriptional Dysregulation

Environmental Toxicology, EarlyView.
ABSTRACT Cadmium (Cd) is a toxic heavy metal strongly implicated in lung adenocarcinoma (LUAD) through mechanisms involving oxidative stress, epigenetic dysregulation, and chronic inflammation. This study aimed to identify Cd‐responsive genes associated with LUAD and to evaluate the protective effects of oxyresveratrol (O‐RES) against Cd‐induced ...
Murat Isıyel, Hamid Ceylan, Yeliz Demir
wiley   +1 more source

<i>ZNF528</i> as a novel driver of metastasis in lung cancer: insights from single-cell transcriptomics. [PDF]

Transl Lung Cancer Res
Li H, Lin Y, Wang Y, Chen X, Xie Y, Yu T, He J, Yin Z, Xia M.   +8 more
europepmc   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

The evolution of non-surgical management in stage III non-small cell lung cancer. [PDF]

BJC Rep
Patel MS, Hammond A, Dee EC, Iyengar P.
europepmc   +1 more source

Plasma Proteomics Analysis Identifying IGFBP2 as a Potential Diagnostic Biomarker for Laryngeal Squamous Cell Carcinoma

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Objective Currently, there are no blood biomarkers available for the early diagnosis of laryngeal squamous cell carcinoma (LSCC). The objective of this study was to search for potential plasma biomarkers for the diagnosis of LSCC. Methods Plasma samples were taken from patients with LSCC and healthy controls for proteomic analysis.
Shuang Teng, Ling‐Mei Qu, Jun‐Jie Liu, Yu‐Shan Li, Zi‐Qi Chen, Shuo Liu, Zhao‐Nan Xu, Meng Jin, Qiu‐Ying Li, Qin Wu, Hong‐Tian Yi, Xian‐Ji Shen, Bing‐Rui Yan, Ya‐Nan Sun   +13 more
wiley   +1 more source

Biomarkers Predictive of Immunotherapy Efficacy in Head and Neck Squamous Cell Carcinoma: Current Insights and Future Perspectives

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT With the approval of immunotherapies by regulatory bodies, head and neck squamous cell carcinoma (HNSCC) treatment has been revolutionized, and anti‐programmed cell death‐1 (anti‐PD‐1) agents are now the standard for platinum‐resistant recurrent/metastatic HNSCC.
Xiao‐Tong Yan, Zhao‐Hong An, Chang‐Ming An   +2 more
wiley   +1 more source